Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy.
Between 1991 and 1996, 372 pregnant women with uncomplicated, multidrug-resistant Plasmodium falciparum malaria, living on the western border of Thailand, were treated with either mefloquine (N = 194), quinine (N = 93) or both drugs (N = 85). Antimalarial treatment was generally well tolerated; the...
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
1998
|
| _version_ | 1826281129033859072 |
|---|---|
| author | Mcgready, R Cho, T Hkirijaroen, L Simpson, J Chongsuphajaisiddhi, T White, N Nosten, F |
| author_facet | Mcgready, R Cho, T Hkirijaroen, L Simpson, J Chongsuphajaisiddhi, T White, N Nosten, F |
| author_sort | Mcgready, R |
| collection | OXFORD |
| description | Between 1991 and 1996, 372 pregnant women with uncomplicated, multidrug-resistant Plasmodium falciparum malaria, living on the western border of Thailand, were treated with either mefloquine (N = 194), quinine (N = 93) or both drugs (N = 85). Antimalarial treatment was generally well tolerated; the most common side-effects were dizziness (42%) and tinnitus (35%) following quinine, and anorexia (23%) and dizziness (36%) following mefloquine. In the patients treated for primary infections with melfloquine, 6% failed to clear their parasitaemia by day 7 and 28% failed by day 42. The corresponding figures for quinine were 4% and 23%, respectively. The failure rates in the 117 women treated for recrudescent infections were higher, the increase being significant for quinine (38%; P = 0.03) but not for mefloquine (37%). The percentage of pregnant women who had patent gametocytaemia on presentation ranged from 4%-19%. Over 50% of the patients were anaemic (haematocrit < 30%) on presentation and 52% of those not anaemic on enrolment developed anaemia during follow-up. Mefloquine and quinine, the only antimalarials generally available for the treatment of highly drug-resistant P. falciparum in pregnancy, give unsatisfactory treatment responses when used as single agents. New, safe and effective regimens are needed for the treatment of pregnant women with multidrug-resistant falciparum malaria. |
| first_indexed | 2024-03-07T00:24:09Z |
| format | Journal article |
| id | oxford-uuid:7d8b43fc-c40b-4271-9eb8-7a884e93d999 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:24:09Z |
| publishDate | 1998 |
| record_format | dspace |
| spelling | oxford-uuid:7d8b43fc-c40b-4271-9eb8-7a884e93d9992022-03-26T21:04:25ZQuinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7d8b43fc-c40b-4271-9eb8-7a884e93d999EnglishSymplectic Elements at Oxford1998Mcgready, RCho, THkirijaroen, LSimpson, JChongsuphajaisiddhi, TWhite, NNosten, FBetween 1991 and 1996, 372 pregnant women with uncomplicated, multidrug-resistant Plasmodium falciparum malaria, living on the western border of Thailand, were treated with either mefloquine (N = 194), quinine (N = 93) or both drugs (N = 85). Antimalarial treatment was generally well tolerated; the most common side-effects were dizziness (42%) and tinnitus (35%) following quinine, and anorexia (23%) and dizziness (36%) following mefloquine. In the patients treated for primary infections with melfloquine, 6% failed to clear their parasitaemia by day 7 and 28% failed by day 42. The corresponding figures for quinine were 4% and 23%, respectively. The failure rates in the 117 women treated for recrudescent infections were higher, the increase being significant for quinine (38%; P = 0.03) but not for mefloquine (37%). The percentage of pregnant women who had patent gametocytaemia on presentation ranged from 4%-19%. Over 50% of the patients were anaemic (haematocrit < 30%) on presentation and 52% of those not anaemic on enrolment developed anaemia during follow-up. Mefloquine and quinine, the only antimalarials generally available for the treatment of highly drug-resistant P. falciparum in pregnancy, give unsatisfactory treatment responses when used as single agents. New, safe and effective regimens are needed for the treatment of pregnant women with multidrug-resistant falciparum malaria. |
| spellingShingle | Mcgready, R Cho, T Hkirijaroen, L Simpson, J Chongsuphajaisiddhi, T White, N Nosten, F Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. |
| title | Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. |
| title_full | Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. |
| title_fullStr | Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. |
| title_full_unstemmed | Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. |
| title_short | Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. |
| title_sort | quinine and mefloquine in the treatment of multidrug resistant plasmodium falciparum malaria in pregnancy |
| work_keys_str_mv | AT mcgreadyr quinineandmefloquineinthetreatmentofmultidrugresistantplasmodiumfalciparummalariainpregnancy AT chot quinineandmefloquineinthetreatmentofmultidrugresistantplasmodiumfalciparummalariainpregnancy AT hkirijaroenl quinineandmefloquineinthetreatmentofmultidrugresistantplasmodiumfalciparummalariainpregnancy AT simpsonj quinineandmefloquineinthetreatmentofmultidrugresistantplasmodiumfalciparummalariainpregnancy AT chongsuphajaisiddhit quinineandmefloquineinthetreatmentofmultidrugresistantplasmodiumfalciparummalariainpregnancy AT whiten quinineandmefloquineinthetreatmentofmultidrugresistantplasmodiumfalciparummalariainpregnancy AT nostenf quinineandmefloquineinthetreatmentofmultidrugresistantplasmodiumfalciparummalariainpregnancy |